by Aaron Levitt | July 22, 2014 9:15 am
I’m sure you’ve heard by now that the market is getting a tad bit frothy. And according to Fed Chairwoman Janet Yellen, two sectors — small caps and biotech stocks — are the frothiest of them all. Except … they’re not. Market commentators have taken Ms. Yellen to school recently over her comments — which managed to send both sectors crashing. Since when does the Fed give investment advice? Here’s Gavyn Davies at the Financial Times with more[1].
The Wall Street Journal’s Money Beat (Steven Russolillo): Biotechs overvalued? Duh! They’re always expensive[2].
Forbes (Agustino Fontevecchia): The drop in biotech prices hasn’t hurt everyone. Meet Italy’s new biotech billionaire[3].
The Motley Fool (Brian Orelli): So should you really heed the Fed’s advice and shun biotech stocks[4]?
Bronte Capital Blog (John Hempton): The Allergan (AGN[5]) vs. Valeant (VRX[6]) biotech battle keeps heating up[7].
Greentech Media (Nicole Litvak): Speaking of high-growth sectors … who is actually paying for all those residential solar installation cropping up across America[8]?
Christian Science Monitor (Eva Botkin-Kowacki): Offshore wind farms are a buffet for seals. No need for reservations[9].
Business Insider (Mamta Badkar): Those wind farms can be expensive. Just ask China. Its debt-to-GDP ratio has exploded[10].
Bloomberg View (Kavitha A. Davidson): A novel idea: All sports Refs should wear GoPro (GPRO[11]) cameras. Think of the replays[12]!
Quartz (Megan Garber): Forget sand. This beach is covered in Legos. Even some hard-to-find ones[13].
Source URL: https://investorplace.com/2014/07/biotech-bubble-agn-vrx/
Copyright ©2024 InvestorPlace unless otherwise noted.